Product Citations 1. Evidence of Toll-like receptor molecules on human platelets. Cognasse F., H. Hamzeh, P.Chavarin, S. Acquart, C. Genin and O. Garraud. Immunology and Cell Biology. Volume 83 Issue 2 Page 196 - April 2005. doi:10.1111/j.1440-1711.2005.01314.x. The following TLR antibodies were cited in this publication: TLR2-PE (IMG-416D), TLR4-PE (IMG-417D), TLR6 (IMG-304A), TLR8-PE (IMG-321D), TLR9-PE (IMG-305D). Applications: Intracellular Flow Cytomety and Cell Surface Flow Cytometry: Figs 1 and 2. A comparison of staining results, intracellular versus cell surface flow cytometry is shown. Cell type: Human platelets 2. TLR7/8-Mediated Activation of Human NK Cells Results in Accessory Cell-Dependent IFN-g Production. Orla M. Hart, Veronica Athie-Morales, Geraldine M. O’Connor, and Clair M. Gardiner. J. Immunol., 175: 1636-1642 (2005). IMGENEX TLR antibodies cited: 1. TLR7 [(IMG-581A) WB, Fig. 1: TLR7 transfected cells and NKL human leukemia cell line. The specificity of the TLR7 antibody has been validated by WB using overexpressed TLR7 in 293T cells in Fig. 1.]. 2. TLR8 [(IMG-321A) WB, Fig. 1: TLR8 transfected cells, NKL human leukemia cell line, and NK92 human lymphoma cell line. The specificity of the TLR8 antibody has been validated by WB using overexpressed TLR8 in 293T cells in Fig. 1]. 3. Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. Clark R, Huang S, Murphy G, Mollet I, Hijnen, D, Muthukuru M, Schnabacher C, E Vonetta, Miller D, Kim J, Lambert J, Kupper T. JEM doi: 10.1084/jem.20071190 (2008). Imgenex antibodies cited: 1. TLR8 (IMG-321A): IF/ICC (human squamous cell carcinoma tumor cells), Fig. 3A. 2. TLR7 (IMG-581A): IF/ICC (human squamous cell carcimona tumor cells), Fig. 3A. 4. Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells. Ofer Levy, Eugenie E Suter, Richard L Miller, and Michael R Wessels. Blood, Apr 2006; 10.1182/blood-2005-12-4821. [TLR8-PE, (IMG-321D): Flow cytometry, Figure 5] 5. Intracellular Signaling Mechanisms Regulating Toll-Like Receptor-Mediated Activation of Eosinophils. Wong CK, PFY Cheung, WK IP and CWK Lam. Am. J. Respir. Cell Mol. Biol.doi:10.1165/rcmb.2006-0457OC (2007), in press. Imgenex antibodies cited (human blood eosinophils and neutrophils from buffy coat): For WB, Fig. 1A: TLR1 (IMG-5012), TLR5 (IMG-664), TLR6 (IMG-304A), TLR7 (IMG-540), TLR8 (IMG-321A), TLR9 (IMG-305A). For Flow (Intracellular) and Flow (Surface), Fig. 1B: TLR1 (IMG-5021), TLR2 (IMG-416C), TLR3 (IMG-315C), TLR4 (IMG-417C), TLR5 (IMG-663C), TLR6 (IMG-304C), TLR7 (IMG-665A), TLR8 (IMG-321C), TLR9 (IMG-305C). 6. Activation of anti-hepatitis C virus responses via Toll-like receptor 7. Lee J, CCN Wu, KJ Lee T-H Chuang, K Katakura, Y-T Liu, M Chan, R Tawatao, M Chung, C Shen, HB Cottam, MMC Lai, E Raz and DA Carson. PNAS 103:1828-1833 (2006). Imgenex antibodies cited in this study: Flow (Intracellular) and Flow (Cell Surface) in human Huh-7 hepatoma cells, Fig. 1A [TLR7 (IMG-665A], [TLR8 (IMG-321C)], and [TLR9 (IMG-305D)]; IHC (paraffin) on Huh-7 cells, normal fibroblasts, HCV-infected liver, and liver carcinoma, Fig 1C-E (TLR7, IMG-665A). The specificity of the TLR7 antibody (IMG-665A) was validated using TLR7 293 transfected cells in Flow (Intracellular) (Supplemental Data, Fig. 5). 7. CD molecules 2006 - Human cell differentiation molecules. Zola H, B Swart, A Banham, S Barry, A Beare, A Bensussan, L Boumsell, CD Buckley, H-J Buhring, G Clark, P Engel, D Fox, B0Q Jin, PJ Macardle, F Malavasi, D Mason, H Stockinger, and X Yang. J Immunological Methods 319:1-5 (2007). Imgenex antibodies cited: TLR8 [IMG-321(A-D)] and TLR10 (IMG-386A). Antibody clones 44C143 (TLR8, IMG-321) and 158C114 (TLR10, IMG-386A) confirmed by the HCDM (Human Cell Differentiation Molecules, previously known as HLDA) 2006 Workshop as TLR8/CD288 and TLR10/CD290, respectively. Also see: http://www.hldaworkshops.org/MoleculeInformation/tabid/54/Default.aspx. 8. STAT3 and STAT5-dependent pathways competitively regulate the pan-differentiation of DC34pos cells into tumor-competent dendritic cells. Cohen P, Koski G, Czerniecki B, Bunting K, Fu X, Wang Z, Zhang W, Carter C, Awad M, Distel C, Nagem H, Paustian C, Johnson T, Tisdale J, Shu S. Immunobiology 112: 1832-1843 (2008). Imgenex antibodies cited [Flow (intracellular), mouse bone marrow cells, Supplementary Fig. S4]: 1. TLR3 FITC (IMG-315C) 2. TLR4 FITC (IMG-5031C) 3. TLR7 (IMG-665A) 4. TLR8 FITC (IMG-321C) 5. TLR9 FITC (IMG-305C) 9. Inhibitors of TLR8 reduce TNF production from human rheumatoid synovial membrane cultures. Sacre S, A Lo, B Gregory, R Simmonds, L Williams, M Feldmann, F Brennan, B Foxwell. J Immunol 181: 8002-8009 (2008). Imgenex antibodies cited [Flow (intracellular), human synovial membrane cells, Fig. 4B]: 1. TLR3-FITC (IMG-315C) 2. TLR8-FITC (IMG-321C) 3. TLR9-FITC (IMG-305C).
|